- Conditions
- Parkinson's Disease, Dyskinesia
- Interventions
- Sarizotan, Placebo
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 204
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma (PDAC)
- Interventions
- M9140
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 8
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- Bintrafusp alfa
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Newark, Delaware • Jacksonville, Florida • Silver Spring, Maryland + 12 more
- Conditions
- Solid Tumor, Leiomyosarcoma, Osteosarcoma
- Interventions
- M6620
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo
- Biological · Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,513 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 49
- States / cities
- Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Precemtabart tocentecan, Bevacizumab, Trifluridine/Tipiracil (FTD-TPI)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 19
- States / cities
- Lone Tree, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 16 more
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
- Interventions
- M7824
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • San Francisco, California • Jacksonville, Florida + 4 more
- Conditions
- Hypopituitarism
- Interventions
- Arimidex (Anastrozole), Placebo, Growth Hormone
- Drug
- Lead sponsor
- Nemours Children's Clinic
- Other
- Eligibility
- 11 Years to 18 Years · Male only
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2010
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Parkinson's Disease, Dyskinesia
- Interventions
- Sarizotan HCl
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 17
- States / cities
- Fountain Valley, California • Sunnyvale, California • Miami, Florida + 14 more
- Conditions
- Infertility
- Interventions
- Not listed
- Lead sponsor
- Inception Fertility Research Institute, LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oocyte Cryopreservation
- Interventions
- Not listed
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 204 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 15
- States / cities
- Fountain Valley, California • Laguna Hills, California • Newport Beach, California + 11 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- Cilengitide 500 mg, Cilengitide 2000 mg
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • Englewood, Colorado • Fort Collins, Colorado + 14 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
- Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Multiple Sclerosis, Physical Activity, Memory Impairment, Cognitive Change
- Interventions
- Treadmill Walking Exercise Training, Stretching-and-toning Exercise Training
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cervical Cancer
- Interventions
- M7824, Carboplatin, Paclitaxel, Bevacizumab, Cisplatin, Radiotherapy
- Drug · Radiation
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Stanford, California • Augusta, Georgia • Henderson, Nevada + 2 more
- Conditions
- Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
- Interventions
- Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Avelumab, Docetaxel
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 792 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 27
- States / cities
- Tuscaloosa, Alabama • Scottsdale , Phoenix, Arizona • Anaheim, California + 24 more
- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine Tablets
- Drug
- Lead sponsor
- Keith Edwards, M.D.
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Latham, New York
- Conditions
- Multiple Sclerosis
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Kansas City, Kansas • New York, New York + 6 more
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 3 more
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- Blood sampling
- Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Rockland, Massachusetts
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Atacicept 75 mg, Atacicept 150 mg, Placebo Comparator
- Drug · Other
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Palo Alto, California • San Diego, California + 13 more
- Conditions
- Unresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Gastric Cancer Third Line
- Interventions
- Avelumab, Irinotecan, Paclitaxel, Best Supportive Care (BSC)
- Drug · Other
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 371 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Denver, Colorado • Pueblo, Colorado • Miami, Florida + 24 more